Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis
- PMID: 31482316
- DOI: 10.1007/s15010-019-01350-1
Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis
Abstract
Objective: Due to the importance of Chronic obstructive pulmonary disease (COPD) as the fourth cause of mortality worldwide and the lack of studies evaluating the prevalence of bacterial infections in disease exacerbation, this systematic review and meta-analysis was performed to determine the prevalence rate of bacterial infections in COPD patients.
Methods: PubMed, ISI Web of Science, and Scopus databases were systematically searched for population-based prevalence studies (1980-2018). MeSH terms for "Bacterial infections" and "AECOPD" were used as search keywords. The selected studies were filtered according to the inclusion and exclusion criteria. Fixed and random-effects models were used for estimation of summary effect sizes. Between-study heterogeneity, as well as publication bias, were calculated.
Results: Finally, 118 out of 31,440 studies were selected. The overall estimation of the prevalence of bacterial infection was 49.59% [95% confidence interval (CI) 0.4418-0.55]. The heterogeneity in estimating the pooled prevalence of bacterial infections was shown in the studies (Cochran Q test: 6615, P < 0.0001, I2 = 98.23%). In addition, S. pneumoniae, H. influenzae, M. catarrhalis, A. baumannii, P. aeruginosa, and S. aureus were the most prevalent reported bacteria.
Conclusions: Our results as the first meta-analysis for the issue demonstrated that bacterial infections are an important risk factor for AECOPD. Further studies must be performed for understanding the exact role of bacterial agents in AECOPD and help physicians for more applicable preventive and therapeutic measurements.
Keywords: AECOPD; Bacterial infections; Meta-analysis; Systematic review.
Similar articles
-
Worldwide prevalence of viral infection in AECOPD patients: A meta-analysis.Microb Pathog. 2017 Dec;113:190-196. doi: 10.1016/j.micpath.2017.10.021. Epub 2017 Oct 14. Microb Pathog. 2017. PMID: 29038056 Free PMC article.
-
Prevalence and risk of viral infection in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis.Mol Biol Rep. 2014 Jul;41(7):4743-51. doi: 10.1007/s11033-014-3345-9. Epub 2014 Apr 2. Mol Biol Rep. 2014. PMID: 24691746
-
[Study on the relationship between airway bacterial infections and acute exacerbations in patients with chronic obstructive pulmonary disease].Zhonghua Liu Xing Bing Xue Za Zhi. 2007 May;28(5):503-6. Zhonghua Liu Xing Bing Xue Za Zhi. 2007. PMID: 17877185 Chinese.
-
Bacterial and Viral Identification Rate in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Korea.Yonsei Med J. 2019 Feb;60(2):216-222. doi: 10.3349/ymj.2019.60.2.216. Yonsei Med J. 2019. PMID: 30666844 Free PMC article.
-
Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis.Respir Res. 2019 Oct 23;20(1):229. doi: 10.1186/s12931-019-1198-4. Respir Res. 2019. PMID: 31647021 Free PMC article.
Cited by
-
Interactions between the lung microbiome and host immunity in chronic obstructive pulmonary disease.Chronic Dis Transl Med. 2023 Apr 3;9(2):104-121. doi: 10.1002/cdt3.66. eCollection 2023 Jun. Chronic Dis Transl Med. 2023. PMID: 37305112 Free PMC article. Review.
-
Development and validation of a nomogram for predicting bacterial infections in patients with acute exacerbation of chronic obstructive pulmonary disease.Exp Ther Med. 2024 Oct 24;29(1):3. doi: 10.3892/etm.2024.12753. eCollection 2025 Jan. Exp Ther Med. 2024. PMID: 39534283 Free PMC article.
-
Harnessing hypoxia: bacterial adaptation and chronic infection in cystic fibrosis.FEMS Microbiol Rev. 2025 Jan 14;49:fuaf018. doi: 10.1093/femsre/fuaf018. FEMS Microbiol Rev. 2025. PMID: 40312783 Free PMC article. Review.
-
Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial.Pilot Feasibility Stud. 2022 Dec 19;8(1):262. doi: 10.1186/s40814-022-01224-8. Pilot Feasibility Stud. 2022. PMID: 36536462 Free PMC article.
-
Shufeng Jiedu capsule for acute exacerbation of chronic obstructive pulmonary disease: a protocol of multicentre, randomised, double-blind, placebo-controlled trial.BMJ Open. 2023 Sep 29;13(9):e070864. doi: 10.1136/bmjopen-2022-070864. BMJ Open. 2023. PMID: 37775286 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical